Premium
Antipyrine clearance in homozygous β‐thalassemia
Author(s) -
Rifkind Arleen B.,
Canale Virginia,
New Maria I.
Publication year - 1976
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1976204476
Subject(s) - thalassemia , medicine , endocrinology , volume of distribution , metabolic clearance rate , clearance rate , beta thalassemia , plasma clearance , chemistry , pharmacokinetics
Serum half‐lives for antipyrine were normal or shorter than normal in 19 subjects between 7 and 23 yr of age with β‐thalassemia major. The mean antipyrine serum half life (±SE) for the group as a whole was 8.5 ± 0.6 hr. The mean antipyrine half‐lives (t½) for the younger subjects were within the range reported for normal children, while the mean t½ for the older males approached the values reported for normal adult males. The mean t½ for the older females was shorter than has been reported for normal adult females. The mean apparent volume of distribution for antipyrine (±SE) in the subjects with thalassemia was 0.69 ± 0.01 L/kg. Thus, total body water appears to be increased in thalassemia. The mean metabolic clearance rate for antipyrine (±SE) in the group as a whole (1.07 ± 0.08 ml/min/kg) is substantially higher than the metabolic clearance rates for antipyrine reported in normal adults. Thus, the relatively short t½s of antipyrine in subjects with thalassemia are attributable to rapid rates of clearance of the drug. The data indicate that antipyrine clearance is unimpaired in patients with thalassemia despite evidence of liver damage and iron overload. Our study supports the proposition that hepatic microsomal hemoprotein synthesis is not adversely affected in homozygous β‐thalassemia.